There are other ongoing trials investigating new agents for DKD, and include investigations into fexofenadine (NCT04224428), niclosamide (NCT04317430) and CSL346 (VEGF-B antagonist monoclonal antibody, NCT04419467). The gene discussed is VEGFB; the disease is diabetic kidney disease.